All Episodes
FDA Watch — 59 episodes
From Price Strategy to Enforcement Risk
When Pricing Pressure Reaches the FDA File: Practical FDA Realities
Governmental Policy Levers: Navigating Drug Pricing Across Agencies and Congress
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 4 – Consumer Products
Breaking Down FDA's Proposed FY27 Budget
What's Next for Cosmetics and Personal Care Products?
A Fresh Look at the State of Human Foods
Where Does FDA Go From Here?
Insights on Evidence and Communication with FDA in Device Submissions
Cautious Optimism Surrounding Rare Diseases and Orphan Drugs
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 3 – Foods
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 2 – Medical Devices
FDA's Regulatory Revisions: Business & Legal Impact on Industry, Part 1 – Pharmaceuticals
Medical Device Regulation, Compliance & Policy, Part 4: Digital Health & Consumers
Medical Device Regulation, Compliance & Policy, Part 3: On False Claims
FDA Reporter Roundtable: A View From the News Desk
'Forever Chemicals' and Cosmetics Oversight in 2026
Medical Device Regulation, Compliance & Policy, Part 2: A Look at Europe & China
FDA's 2026 Food Priorities
Medical Device Regulation, Compliance & Policy, Part 1: LDTs in Focus
FDA's Evolving Approach to Medical Device Reviews
Inside FDA Pharma Policy Development
Year-End Review & Look Ahead
Deregulation, AI & More with Dr. Ritu Nalubola
Pharmaceutical Regulation, Compliance & Policy, Part 4: Dispute Resolution for Drugs and Biological Products
Key Issues Shaping Cosmetics and Personal Care Oversight
How Industry Is Adapting to FDA's Food Shifts
Pharmaceutical Regulation, Compliance & Policy, Part 3: A Close Look at Generic Drugs
Pharmaceutical Regulation, Compliance & Policy, Part 2: Navigating the New Enforcement Environment
Examining CDRH, Device Innovation & Agency Communication
A Look at FDA's Drug Review Reset
Pharmaceutical Regulation, Compliance & Policy, Part 1: The Evolving Regulatory Landscape of Rare Diseases
Unpacking OMUFA
FDA's Fight Against Ultraprocessed Foods
Dissecting the Direction of CDER and CBER with Paul Kim
Medical Device Oversight in a Changing Landscape
Vaccines, Pharmaceutical Policy & FDA's Next Moves
FDA's Past, Present & Future with John Taylor
The Top 3 Developments of 2025 in Pharma, Devices, Cosmetics & Food
Breaking Down Cosmetics Safety, Imports & MoCRA
AI, Medical Products & FDA, Part 3: AI in Drug & Device Commercialization
Homing in on Food Supply, Tariffs & Infant Formula
AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development
Devices, Disruption & the Road Ahead
Breaking Down Pharma in the Current Environment
The State of Protection, Innovation & Communication at FDA
AI, Medical Products & FDA, Part 1: AI Overview in Life Sciences
Examining the Cosmetics Compliance and Enforcement Landscape
A New Era of Unprecedented Change
The Latest in FDA's Focus on Foods
What's Happening in Software and Device Regulation
The Evolution of Clinical Trials
Navigating FDA's Future: Janet Woodcock on the Evolving Regulatory Landscape
A Deep Dive Into MoCRA
Food Regulation and Safety Under the New Administration
The New-Look FDA: What's on the Horizon?
What's Coming in Device, Cybersecurity, and Digital Health Product Regulation
Key Pharmaceutical Regulation Issues for the New Administration
Trailer